BidaskClub upgraded shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a sell rating to a hold rating in a research note released on Friday.

CVRS has been the topic of a number of other reports. ValuEngine raised shares of Corindus Vascular Robotics from a sell rating to a hold rating in a report on Wednesday, August 23rd. Zacks Investment Research raised shares of Corindus Vascular Robotics from a hold rating to a buy rating and set a $2.00 price objective on the stock in a report on Tuesday, July 11th. Cowen and Company set a $3.00 price objective on shares of Corindus Vascular Robotics and gave the company a buy rating in a report on Wednesday, August 9th. Finally, B. Riley reissued a buy rating and set a $3.00 price objective on shares of Corindus Vascular Robotics in a report on Monday, May 15th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of $2.58.

Shares of Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.84 on Friday. Corindus Vascular Robotics has a one year low of $0.40 and a one year high of $2.25. The company’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.34. The company’s market capitalization is $344.62 million.

Corindus Vascular Robotics (NYSEMKT:CVRS) last released its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $2.26 million for the quarter, compared to analyst estimates of $3.10 million. Corindus Vascular Robotics had a negative net margin of 1,272.20% and a negative return on equity of 181.63%. On average, equities research analysts predict that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Corindus Vascular Robotics Inc (CVRS) Rating Increased to Hold at BidaskClub” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/corindus-vascular-robotics-inc-cvrs-rating-increased-to-hold-at-bidaskclub/1528548.html.

Several large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in Corindus Vascular Robotics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock valued at $214,000 after buying an additional 9,684 shares during the last quarter. California State Teachers Retirement System raised its stake in Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after buying an additional 38,000 shares during the last quarter. State Street Corp raised its stake in Corindus Vascular Robotics by 44.3% in the second quarter. State Street Corp now owns 926,439 shares of the medical equipment provider’s stock valued at $1,724,000 after buying an additional 284,507 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 35,086 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Corindus Vascular Robotics by 57.6% in the second quarter. Vanguard Group Inc. now owns 3,279,185 shares of the medical equipment provider’s stock valued at $6,100,000 after buying an additional 1,198,384 shares during the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.